Filters
No claim for damages as a result of participation in clinical drug trials
A European Perspective #1 | GERMANY | The Frankfurt am Main Regional Court confirms: No reduction in the burden of proof (presumption of causality) pursuant to Section 84 (2) of the German Medicines Act (AMG) for IMP (not even by analogy) and no liability on the part of the sponsor in the event of (insufficient) risk information provided by the investigating physician.
7 of 9 Insights
Request for a Preliminary Ruling by Federal Court of Justice on the Prohibition of Advertising for Remote Medical Treatments under Section 9 HWG
The Special Fund for Infrastructure and Climate Neutrality
EU Inc. – The 28th Regime: How the European Commission intends to revolutionise the formation of companies
Prediction Markets in Germany and Europe: Legal Status, Risks, and Opportunities
Strategic management of open source in the automotive industry — Legal framework and compliance requirements
More Than Share and Asset Deals: Innovative Transaction Structures for MedTech Companies
2026 Lexology Panoramic Guide on Distribution & Agency in Germany
German Special Fund for Infrastructure and Climate Neutrality
Opportunities for non-EU Companies
